U.S. markets close in 6 hours 21 minutes

Ardelyx, Inc. (ARDX)

NasdaqGM - NasdaqGM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
6.65+0.04 (+0.61%)
A partir del 09:39AM EDT. Mercado abierto.

Ardelyx, Inc.

400 Fifth Avenue
Suite 210
Waltham, MA 02451
United States
510 745 1700
https://www.ardelyx.com

Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 267

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Michael G. RaabPresident, CEO & Director1.28MN/D1965
Ms. Susan RodriguezChief Commercial Officer760.77kN/D1964
Dr. Laura A. Williams M.D., M.P.H.Chief Medical Officer873.8kN/D1964
Mr. Robert FelschSenior VP of Finance & Chief Accounting OfficerN/DN/DN/D
Ms. Elizabeth A. Grammer Esq.Chief Legal & Administrative Officer and Secretary623.7kN/D1964
Ms. Caitlin LowieVice President of Corporate Communications & Investor RelationsN/DN/DN/D
Ms. Charon Spencer Sr.Chief Human Resources OfficerN/DN/DN/D
Mr. David P. RosenbaumChief Development Officer645.4kN/D1961
Mr. Robert C. BlanksChief Regulatory Affairs & Quality Assurance Officer590.8kN/D1960
Ms. Kimia KeshtbodManager of Corporate Communications & Investor RelationsN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Gestión corporativa

La calificación ISS Governance QuickScore de Ardelyx, Inc. a partir del 29 de abril de 2024 es 8. Las puntuaciones principales son Auditoría: 9; Junta: 6; Derechos del accionista: 8; Compensación: 8.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.